01Anthropic's two-pronged strategy

Why did Anthropic split Claude and Fable / Mythos into two tracks? Until now only part of the answer has been told, so let us lay it out again. Claude plays the role of supplying something dependable to companies that already use it. It runs under the public rules that drug manufacturing and quality control must follow (GxP), it has been checked against the law and internal standards (compliance), and it serves work where keeping the business running comes first. Fable, by contrast, plays the role of pushing the frontier: research, AI that acts on its own (agents), reading long documents, new ways of reasoning. The two are kept separate so that, even if Fable becomes a target of regulation, it does not directly hit users' day-to-day work.

This split resembles how Microsoft keeps Windows (dependable supply) alongside Surface (an aggressive product), or how Apple keeps the Mac (continuity) alongside Vision Pro (a new field). It is a deliberate choice not to chase both goals under a single brand at once. Anthropic landed here because it is weighing long-term trust and short-term competition at the same time.

02Inheritance and development of Constitutional AI

The technical backbone of Anthropic is a mechanism it calls Constitutional AI. The idea is to write out, in advance, the principles an AI should follow as a text (a "Constitution"), and then have the AI check its own answers against those principles and correct them. The safety of the Claude series leans heavily on this mechanism. It is natural to assume that Fable / Mythos carries the same lineage forward.

What is easy to miss is that this approach works not only "for safety" but also as a foundation for raising performance over the long run. An AI's ability to review its own judgments, notice contradictions, and fix them ultimately improves the quality of its reasoning. If Fable holds its own as a frontier model — an experimental model that pushes the limits of performance — that becomes proof the Constitutional AI direction was technically sound.

03What it means to get John Jumper

In June 2026, news of Anthropic's acquisition of John Jumper from Google DeepMind sent shockwaves through the industry. Jumper is a co-inventor of AlphaFold and co-recipient of the 2024 Nobel Prize in Chemistry. His specialty was life sciences, especially protein structure prediction. The industry was curious as to why he was going to Anthropic.

Two readings make sense. The first is that Anthropic is getting ready to move seriously into applying AI to the life sciences — finding new drugs (drug discovery), designing proteins, and reading genetic information (genomics, the analysis of an organism's genes). Life science may be the next main battleground for the Fable series. The second is a research judgment: sharpening Constitutional AI further calls for Jumper's scientific rigor. Either way, it is a hire that carries weight when you try to read where Anthropic is heading.

From a pharmaceutical industry perspective, if Anthropic were to enter life sciences in earnest, it would mean expanded opportunities for collaboration with pharmaceutical companies. It has a wide range of applications, including drug discovery support, clinical trial design, and the drafting of regulatory documents.

04Industry spillover -- China's independent ecosystem

In response to the Fable regulation, China is hurrying to build its own AI sphere. DeepSeek's public pledge to ship "a Fable 5-class model within a year" is both a guard against the regulation and a sign that catching up technically looks like a realistic option. By narrowing down how much the model has to compute — techniques such as Sparse Attention, which cut the amount of processing — DeepSeek lowers the cost of running AI, and it has grown into a presence that threatens the US models.

For China's AI industry this is a chance to grow on its own. There is an irony in the shape of it: US regulation ends up pushing China toward independence. Over the long term the world's AI ecosystem looks set to split into a US camp and a Chinese camp, and the open question is where Europe and Japan choose to stand in between.

05Sridhar Vembu's review

Sridhar Vembu, the founder of Zoho, has long commented on how regulation and the AI industry relate. At the time of writing, his specific remarks on the Fable regulation itself are limited. Even so, the idea he has pressed for years — "Software Sovereignty," the view that a country should keep hold of its own critical software rather than leaving it to other nations — now carries fresh weight.

The core of Vembu's argument is that countries should not rely on foreign companies' AI for their critical business systems. This is an argument that applies not only to China, but also to India, Europe, and Japan. The Fable regulation gave that claim concrete grounding. If an AI vendor in one country becomes a target of regulation, the work in other countries that relied on it can grind to a halt. Choosing AI as a matter of sovereignty has become a real management problem.

"Twenty years ago, we talked about 'data sovereignty.' Ten years ago, we moved on to 'cloud sovereignty.' Now we're asking 'AI sovereignty.' The question is always the same -- who owns the critical layers of your business?" -- Sridhar Vembu, Zoho Founder, 2025, LinkedIn post

06Regulation becomes the norm

The Fable regulation is probably not a one-off event but the first instance of regulation that is about to become routine — several industry commentators say as much. Once an AI model is treated as a strategic asset that tips the balance of power between nations (a geopolitical asset), we should expect the same kind of regulation to come again and again. GPT-family, Gemini-family, and Llama-family models could all be regulated the same way in time.

For the compliance departments of pharmaceutical companies — the teams that make sure the business follows the law and internal rules — this becomes a new running cost. They have to watch constantly which AI vendors are under regulation, respond when usage terms change, and stand ready to switch vendors when they must. In other words, the way a company tracks which software it owns and what its contracts say (Software Asset Management) now has to stretch to cover AI vendors too.

07Long-term stance of the pharmaceutical industry

We conclude this series with three long-term positions the pharmaceutical industry should take toward Fable and the next generation of AI trends.

First, spread the design across several vendors and several countries. From the earliest stage, build an architecture that does not lean too hard on a single company (Anthropic) or a single country (the United States). This matters not only for spreading regulatory risk but also for keeping a range of technical options open.

Second, let the compliance team learn to read international affairs. When choosing an AI vendor, add a yardstick for the risk that comes from conflict between nations (geopolitical risk), not just performance and legal compliance. In practice this means refreshing what compliance staff are trained on.

Third, hold on to the long view. Do not let short-term switching costs pull you toward a vendor that is not the best technical fit. Making a habit of stepping back every so often, on a 3-5 year horizon, to ask where the whole industry is heading is what sustains an advantage over time.

08Conclusion of this series

Through three retrospectives on Fable 5.0, we traced everything from the name of the AI model to regulation and diplomacy to the direction of the next generation. AI is no longer a purely technical subject; it has become an area where technology, regulation, geopolitics, and industrial structure are intricately intertwined. As a player, the pharmaceutical industry is required to confront this complexity at all levels: technology selection, compliance, research, and patient support.

What we can do from tomorrow is to carefully carry out the tasks at hand. At the same time, make it a habit to regularly review trends in the industry as a whole and check your own position. Every day is a good day. A perspective that continues to look at both today's work and tomorrow's industry supports long-term trust.